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The coordination of complex tumor processes
requires cells to rapidly modify their phenotype
and is achieved by direct cell-cell communication
through gap junction channels composed of con-
nexins. Previous reports have suggested that gap
junctions are tumor suppressive based on connexin
43 (Cx43), but this does not take into account differ-
ences in connexin-mediated ion selectivity and
intercellular communication rate that drive gap junc-
tion diversity. We find that glioblastoma cancer
stem cells (CSCs) possess functional gap junctions
that can be targeted using clinically relevant com-
pounds to reduce self-renewal and tumor growth.
Our analysis reveals that CSCs express Cx46, while
Cx43 is predominantly expressed in non-CSCs. Dur-
ing differentiation, Cx46 is reduced, while Cx43 is
increased, and targeting Cx46 compromises CSC
maintenance. The difference between Cx46 and
Cx43 is reflected in elevated cell-cell communica-
tion and reduced resting membrane potential in
CSCs. Our data demonstrate a pro-tumorigenic
role for gap junctions that is dependent on connexin
expression.INTRODUCTION
Glioblastoma (GBM) is the most common primary malignant
brain tumor and remains uniformly fatal despite aggressiveCtherapies including surgery, radiation, and chemotherapy (Stupp
et al., 2009). Many barriers to effectively treating GBM exist
and include the development of therapeutic resistance and inter-
and intra-tumor heterogeneity. While there is an ongoing effort to
identify key molecular alterations driving GBM, targeted thera-
pies based on these events have not effectively translated into
patient survival benefits. GBM possesses a high degree of
cellular heterogeneity and contains self-renewing, tumorigenic
cancer stem cells (CSCs) that contribute to tumor propagation
(Galli et al., 2004; Ignatova et al., 2002; Singh et al., 2003,
2004) and therapeutic resistance (Bao et al., 2006; Liu et al.,
2006). The integration of CSCs into tumor models presents an
opportunity to develop more effective GBM therapies, and
CSC-directed therapies have shown promise in pre-clinical
studies.
CSC interactions with the surrounding microenvironment
dictate the balance between self-renewal and differentiation
via growth factors, extracellular matrix, and communication
with adjacent cells (Visvader and Lindeman, 2012). Direct
cell-cell communication synchronizes groups of cells to
execute coordinated programs required for growth, differentia-
tion, and therapeutic response (Naus and Laird, 2010). The
rapid diffusion of essential signaling molecules, such as cyclic
AMP, inositol 1,4,5-tri-phosphate, ions, and nutrients between
adjacent cells, is facilitated by gap junctions (Evans and Martin,
2002). Gap junctions are formed by six connexin subunits that
assemble at the interface between adjacent cells, allowing
direct cell-cell communication for molecules less than 1 kDa
in size. The connexin family contains over 20 proteins with tis-
sue-specific expression and function that are named according
to predicted molecular weight. Diversity in connexin expression
is responsible for differential ion permeability and varying diffu-
sion rates (Elfgang et al., 1995; Lin et al., 2004). Switching ofell Reports 11, 1031–1042, May 19, 2015 ª2015 The Authors 1031
Figure 1. Morphological and Functional
Detection of Gap Junctions in CSCs
(A) Electron microscopy evaluation of thin sections
from a xenograft tumor and GBM tumorspheres
(T387) reveal the presence of gap junction struc-
tures. Arrows indicate gap junction structures and
scale bar represents 300 nm.
(B) Functional gap junctions in CSCs were evalu-
ated using a microinjection strategy in which the
parental cell (P) was injected with a large IgG (red)
incapable of leaving the cell and a smaller dye
(green), which was visualized spreading to adjacent
cells using time-lapse imaging.
(C) Representative micrographs demonstrate the
spread of dyes (lucifer yellow and 2NBDG, a fluo-
rescent glucose analog) in CSCs derived from
xenografts T4121 and T387.connexin subunits occurs during development as a result of
changes required during tissue maturation (Banerjee et al.,
2011), i.e., transitioning from a stem cell to a differentiated
state. Connexin function is required for normal physiology,
and dysfunction in connexins has been linked to a variety of
disorders, including deafness (connexin 26 [Cx26]) (Gerido
et al., 2007), peripheral neuropathy (Cx32) (Scherer and Kleopa,
2012), and cataracts (Cx46 and Cx50) (Beyer and Berthoud,
2014).
One of the most extensively studied connexins is Cx43,
which has served as a paradigm for gap junction function dur-
ing development and disease. Cx43 is essential for neural pro-
genitor cell (NPC) proliferation and self-renewal (Cheng et al.,
2004; Elias et al., 2007), but is decreased in GBM compared
with lower grade tumors (Soroceanu et al., 2001). CSCs ex-
press low levels of Cx43, and overexpression of Cx43 in
CSCs increased GBM latency (Yu et al., 2012). Similar findings
in other advanced cancers have served as a basis for the hy-
pothesis that gap junctions act as tumor suppressors (Kandouz
and Batist, 2010). However, this role for gap junctions fails to
model the connexin diversity driving communication rate and1032 Cell Reports 11, 1031–1042, May 19, 2015 ª2015 The Authorsion specificity in a cell-type-dependent
manner (Evans and Martin, 2002). Based
on the elevated cellular density in GBM,
which increases the opportunity for direct
cell communication, and the dependence
of CSC maintenance on cell-cell interac-
tions, we interrogated the function of con-
nexins in GBM. While previous reports
suggest that gap junctions have a tu-
mor-suppressive function, we now report
that gap junctions are essential for GBM
growth. We identified Cx46 as enriched
in CSCs and essential for their mainte-
nance and negatively correlating with
GBM patient survival. Our data support
a model where the tumor-promoting func-
tion of gap junctions is dependent on the
composition of connexin subunits and im-pacts intercellular communication, resting membrane potential,
and CSC maintenance.
RESULTS
Gap Junctions Are Present in GBM and CSCs
Previous work in GBM demonstrated a tumor-suppressive role
for gap junctions based on reduced expression of Cx43 in GBM
(Soroceanu et al., 2001) and CSCs (Yu et al., 2012). Given the
importance of CSCs for tumor progression, we sought to deter-
mine whether gap junctions were present and functional in
CSCs.Wefirst usedelectronmicroscopy toexamine thinsections
of GBM xenografts and CSC spheres grown in vitro and found
structures characteristic of gap junctions, i.e., the plasma
membranes of two adjacent cells were in close proximity but
separated by a narrow gap (Figure 1A). To confirm whether
functional cell-cell communication occurred among CSCs, we
microinjected a fluorescent dye into single CSCs in monolayer
cultures and assessed cell-cell communication by tracking
diffusion of the injected dye. To achieve this, we took advantage
of a co-injection strategy in which the parental cell was injected
Figure 2. Functional Analysis of Gap Junc-
tions in CSCs
(A and B) Micrographs (A) and quantitative image
analysis (B) demonstrate that diffusion of the small-
molecular-weight fluorescent dye microinjected
into CSCs was efficiently blocked by gap junction
inhibitors 1-octanol (1 mM) and CBX (100 mM).
Data in graphs represent mean values ± SD; *p <
0.05, **p < 0.01 as assessed by one-way ANOVA.with a fluorescent IgG too large to be transferred to adjacent cells
(150 kDa) in combination with fluorescent dyes small enough to
diffuse between adjacent cells through gap junctions (<1 kDa,
Figure 1B). Over time, the dye rapidly diffused to adjacent cells
as observed by time-lapse imaging (Figure 1C). Using this
approach with multiple fluorescent dyes (lucifer yellow and the
glucose analog 2NBGD), we observed direct cell-cell communi-
cationbetweenCSCsaswell asbetweennon-CSCsandbetween
CSCs and non-CSCs in a bidirectional manner (data not shown).
To confirm that this diffusion was mediated by gap junctions,
we utilized several compounds with gap junction inhibitory prop-
erties: carbenoxolone (CBX), 1-heptanol, mefloquine (MEF), and
1-octanol (Juszczak and Swiergiel, 2009; Rozental et al., 2001).
CBX is approved for use in the United Kingdom for inflammation
and gastric ulcers, MEF is an anti-malarial agent, 1-heptanol and
1-octanol are approved for use in the United States and found as
additives in perfume, and 1-octanol also currently is being eval-
uated for efficacy against essential tremor (Nahab et al., 2011).
We repeated the single-cell injection studies in the presence of
either CBX or 1-octanol and observed a significant reduction in
dye diffusion in CSCs (Figure 2) and non-CSCs (data not shown).
We further confirmed the efficacy of all four inhibitors using a
flow cytometry-based assay, and each inhibitor significantly
attenuated dye diffusion in CSCs derived frommultiple xenograft
specimens (data not shown). These data confirm the presence
of functional gap junctions between CSCs.
Gap Junction Inhibitors Are Toxic to CSCs and Inhibit
CSC Proliferation and Self-Renewal
Based on our observations of functional gap junctions between
CSCs, we wanted to determine whether gap junction inhibitorsCell Reports 11, 1031–10could be used to target CSCs. We tested
the impact of CBX (100 mM) and 1-octanol
(1 mM) on the growth of CSCs and non-
CSCs. In CSCs derived from multiple
xenografts, we observed a significant
reduction in CSC growth. The inhibitory
effect on CSCs was greater than what
was observed in non-CSCs in optimized
media for each cell type (Figure 3A). How-
ever, when identical media conditions
were used, the growth of both CSCs and
non-CSCs was impacted (Figure S1A).
To determine whether these gap junction
inhibitors attenuated self-renewal, we
performed in vitro limiting dilution studies
across a range of CBX and 1-octanol con-centrations, and we found that gap junction inhibitors reduced
sphere formation and stem cell frequency (Figures 3B and 3C).
To determine the mechanism by which gap junction inhibitors
reduced proliferation and self-renewal, we evaluated apoptotic
events using a caspase-3/7 activity assay and found a sig-
nificant increase in caspase-3/7 activity when CSCs were
exposed to gap junction inhibitors (Figure S1B). To address
whether the inhibitory effect of CBX and 1-octanol was CSC
specific, we compared the IC50 for CSCs and NPCs and
found that both inhibitors had a significantly lower IC50 in
CSCs compared to NPCs (36.5 versus 49.5 mM for CBX and
2.1 versus 2.4 mM for 1-octanol, p < 0.01, sigmoidal dose
response/comparison of fits, data not shown). We then tested
cell viability across CSCs from multiple GBM xenografts
after a 3-day treatment with the compounds at the IC50 values
and found a significant reduction in viability compared with
NPCs (Figure S1C). No difference in viability was observed
with 4-methyl-heptanol, an isomer of 1-octanol lacking gap
junction inhibitory activity (Figure S1C). These data demon-
strate that multiple gap junction inhibitors can target CSC pro-
liferation and self-renewal.
Gap Junction Inhibitors Attenuate Tumor Growth In Vivo
and Greatly Increase Tumor Latency in Combination
with Temozolomide
Based on our in vitro data, we investigated the efficacy of gap
junction inhibitors on tumor growth in vivo. Using a subcutane-
ous xenograft model, we evaluated the effect of gap junction
inhibitors on tumor growth. After detection of palpable subcu-
taneous tumors, the mice were randomized and treated with a
gap junction inhibitor (CBX or 1-octanol), temozolomide (TMZ),42, May 19, 2015 ª2015 The Authors 1033
Figure 3. Gap Junction Inhibitors Suppress CSC Proliferation and Self-Renewal
(A) Representative growth curves of CSCs and non-CSCs derived from xenografts T387 and T4121 treated with 1-octanol (1 mM) reveal that CSC growth was
significantly attenuated, whereas non-CSC growth was reduced to a lesser degree.
(B and C) Sphere formation from 10 cells per well (B) and limiting dilution analysis (C) reveal that 1-octanol (1 mM) and CBX (100 mM) significantly attenuated CSC
self-renewal and reduced stem cell frequency.
(D) Treatment of established subcutaneous tumors with 1-octanol (left) or CBX (right) significantly decreased tumor growth and had an additive effect when
combined with TMZ.
(E) Treatment of established intracranial tumors with CBX (left) or 1-octanol alone (center) or in combination with TMZ (right) extended survival and increased
tumor latency compared with control or a chemical isoform of 1-octanol (4-methyl-heptanol) without gap junction inhibitory activity.
Stem cell frequencies are provided directly on each plot; data in graphs represent mean values ± SD; *p < 0.05, **p < 0.01, ***p < 0.001 as assessed by one-way
ANOVA. See also Figure S1.
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or a combination of a gap junction inhibitor and TMZ, and tumor
volume was monitored over time. Tumor growth was signifi-
cantly delayed by treatment with either a gap junction inhibitor
or TMZ, the standard chemotherapeutic treatment for GBM (Fig-
ure 3D). An additive effect on tumor growth suppression was
observed when a gap junction inhibitor and TMZ were combined
(Figure 3D). We also used an orthotopic xenograft model to
assess the anti-tumor effect of 1-octanol alone and in combina-
tion with TMZ. Treatment of an established intracranial tumor
with CBX or 1-octanol initiated 14 days after tumor cell inocula-
tion increased tumor latency andmedian survival compared with
control treatments, indicating a strong correlation between gap
junction inhibitory activity and anti-tumor effect (Figure 3E).
Based on the ability of 1-octanol to significantly increase tumor
latency, we combined 1-octanol with the chemotherapeutic
TMZ. The 1-octanol treatment enhanced the effect of TMZ, as
the combination treatment robustly increased the survival of
mice (Figure 3E), decreased proliferation, and induced apoptosis
(data not shown).
As gap junction inhibitors augmented the anti-tumor effect of
TMZ in both subcutaneous and orthotopic xenograft models,
we next interrogated whether gap junction inhibitors sensitized
TMZ-resistant GBM cells to TMZ. Using an in vitro model, we
compared the growth of TMZ-resistant GBM cells treated with
TMZ alone with those treated with TMZ and CBX in combination.
This combined treatment significantly inhibited the growth of the
resistant tumor cells and decreased the rate of symmetric cell
division (Figures S1D and S1E). Taken together, these data
demonstrate the anti-tumor effect of gap junction inhibition in
pre-clinical GBM models and suggest increased efficacy when
combined with TMZ. In addition, these data indicate that the
growth of TMZ-resistant cells can be attenuated by gap junction
inhibition, which correlated with a sensitization of TMZ-resistant
cells to TMZ.
Connexin Subunit Expression Analysis Demonstrates
that Cx46 Is Enriched in CSCs
Based on our identification of functional gap junctions in CSCs
and the efficacy of gap junction inhibitors on attenuating CSC
maintenance, we wanted to determine which connexins were
responsible for these effects. We evaluated the expression of
different connexins in NPCs and well-established human GBM-
derived xenograft tumors (T4121 and T387), consisting of popu-
lations of CSCs and non-CSCs with functionally high (CSC) or
low (non-CSC) tumor initiation capabilities. We performed
qPCR and found that Cx46 was significantly elevated in CSCs
compared with NPCs and that Cx43 was elevated in NPCs
compared with CSCs (Figure S2A). Cx46 has not been well
described in many tissues outside of the eye (Gong et al.,
1997), where it has been linked to congenital cataract formation
(Mackay et al., 1999). It also has been reported that Cx46 is
reciprocally regulated with Cx43 (Banerjee et al., 2011) and
may be responsive to hypoxia (Molina and Takemoto, 2012), a
microenvironmental CSC maintenance factor (Li et al., 2009;
Soeda et al., 2009).
To evaluate differences between CSCs and non-CSCs, we
performed immunoblotting analysis with an antibody validated
by detection of the product of a cDNA encoding human Cx46Cand the absence of Cx46 in Cx46 knockout mouse lens tissue.
This antibody revealed that Cx46 was enriched in CD133+
CSCs compared with matched CD133 non-CSCs from the
same tumor (Figure 4A). Cx43 was expressed at much lower
levels in CSCs than in non-CSCs (Figure 4A). To determine
whether this differential Cx43 expression was regulated epige-
netically, we analyzed publically available chromatin immuno-
precipitation followed by sequencing (ChIP-seq) datasets
containing H3K27ac information of three primary GBM samples
cultured under stem cell growth conditions (TPC) or differentia-
tion conditions (DGC) (Figure S2B; Suva` et al., 2014). We found
striking activation of promoter and enhancer elements sur-
rounding the Cx43 gene locus in the differentiated glioma cells,
suggesting that the differences we observed in Cx43 protein
and RNA levels were governed epigenetically through histone
modifications. The elevated expression of Cx46 in CSCs also
was detected when CSCs were enriched directly from xeno-
grafts based on CD133 or an alternative CSC marker, integrin
a6 (Lathia et al., 2010; Figure 4B; Figure S2C). Our expression
analysis revealed that Cx46 was expressed by CSCs, while
Cx43 was expressed by non-CSCs. As CSCs differentiate,
the expression of molecules involved in CSC maintenance is
lost, and the expression of differentiation-associated molecules
increases. To evaluate whether Cx46 and Cx43 are located on
different ends of the differentiation spectrum, we differentiated
CSCs by removing growth factors and adding 10% serum and
observed a concomitant decrease in Cx46 along with an in-
crease in Cx43 expression (Figure 4C). Taken together, these
data demonstrate that Cx46 is enriched in CSCs and that
Cx43 is expressed in non-CSCs and increases upon CSC
differentiation.
Cx46 Is Essential for CSC Proliferation, Self-Renewal,
and Tumor Initiation
To interrogate the biological role of Cx46 in CSC maintenance,
we generated non-overlapping small hairpin RNA (shRNA)
constructs against the Cx46 mRNA (Figure S2D). We confirmed
that these constructs reduced Cx46 expression in CSCs (Fig-
ure 4D; Figure S2E). After transducing these shRNA constructs
into CSCs via lentivirus, we compared cellular functions of
transduced CSCs with those receiving a non-targeting control
shRNA (NT). Reduced Cx46 expression resulted in decreased
proliferation (Figure 4E) and self-renewal (Figures 4F and 4G),
as well as reduced stem cell frequency (Figure 4G). In addition,
the decreases in proliferation and self-renewal were accompa-
nied by an increase in cell death as assessed by caspase-3/7
activity (Figure S2F). To determine whether Cx46 was essen-
tial for tumor initiation, an in vivo surrogate assay of CSC
self-renewal, we transduced CSCs with NT or Cx46 shRNA
constructs and evaluated their tumor formation ability by
transplanting the cells into the brains of immunocompromised
mice. Across multiple cell dosages (1,000 and 10,000 cells),
CSCs containing the NT construct uniformly formed tumors,
whereas CSCs transduced with Cx46-targeting shRNAs
demonstrated significantly increased tumor latency and a
reduced tumor formation capacity (Figure 4H). Taken together,
these data demonstrate that Cx46 is essential for CSC
maintenance.ell Reports 11, 1031–1042, May 19, 2015 ª2015 The Authors 1035
Figure 4. Cx46 Is Enriched in CSCs and Reduction Compromises Proliferation, Self-Renewal, and Tumor Initiation Activity of CSCs
(A) Immunoblotting analysis (A) of CSC and non-CSC populations derived from subcutaneous xenografts (T4121 and T387) reveals that Cx46
expression was elevated in CSCs compared with non-CSCs, whereas Cx43 expression was reduced in CSCs compared with non-CSCs and NPCs.
(B) Immunoblots for Cx46 and Cx43 demonstrate differences in a patient-derived xenograft (T4121) sorted immediately after dissociation for the CSC markers
CD133 and integrin a6 (Int a6).
(C) Immunoblotting analysis of CSCs derived from xenograft T4121 reveals that Cx46 expression was reduced during differentiation, whereas Cx43 expression
was increased.
(D–G) Cx46 was depleted by lentiviral delivery of shRNA using non-overlapping constructs as demonstrated by representative immunoblots from CSCs derived
from xenograft T4121 (D), where Cx46 was reduced by knockdown (KD) constructs compared with the NT control. Cx46 KD suppressed proliferation (E), sphere
formation (F), and stem cell frequency (G).
(legend continued on next page)
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Figure 5. CSCs and Non-CSCs Express
Different Connexins that Facilitate Differen-
tial Rates of Cell-Cell Communication and
Resting Membrane Potential
(A) Schematic depicts assay to evaluate the for-
mation of new gap junctions in which the dye
diffuses to unlabeled cells upon the establishment
of gap junctions.
(B) Relative diffusion after 8 hr differs between
CSCs and non-CSCs derived from the T4121 GBM
xenograft.
(C) After Cx46 KD, relative diffusion is significantly
reduced compared with the NT control.
(D) Electrophysiological analysis of the outward
currents recorded in CSCs and non-CSCs dem-
onstrates a reduction in CSC currents compared
with non-CSCs.
(E and F) Voltage-clamp analysis (E) demonstrates
that the resting membrane potential of CSCs is
higher than that of non-CSCs. Cx43 was depleted
by lentiviral delivery of shRNA using non-over-
lapping constructs against different parts of the
gene, and representative immunoblots from non-
CSCs derived from xenograft T4121 (F) demon-
strate that Cx43 KD increased Cx46 expression
compared with the NT control. Similar results were
obtained in T387 (data not shown).
(G) Summary graph of voltage-clamp analysis
demonstrates that the resting membrane potential
of CSCs was higher than that of non-CSCs. Cx43
KD in non-CSCs resulted in an increase in resting
membrane potential. Red box indicates resting
membrane potential range of CSCs.
Data in graphs represent mean values ± SD; *p <
0.05, **p < 0.01, ***p < 0.001 as assessed by one-
way ANOVA. Current traces were plotted every
20 mV for clarity, and the calibration bar represents
2.5 ms and 5 pA/pF.CSCs Predominantly Express Cx46, and Non-CSCs
ExpressCx43, Resulting inDifferent Diffusion Rates and
Resting Membrane Potential
To determine the physiological consequence of differential con-
nexin subunit expression by CSCs and non-CSCs, we evaluated
dye diffusion rates between cells and restingmembrane potential,
as Cx46 and Cx43 have different diffusion rates and ion selectivity
(Elfgang et al., 1995; Lin et al., 2004). Cx43 allows for the passage
of both cations and anions, whereas Cx46 only allows for the pas-
sage of cations (Harris, 2001; Qu and Dahl, 2002; Trexler et al.,
2000; Wang and Veenstra, 1997). Using a dye-diffusion-based
assay to measure de novo gap junction formation (Figure 5A), we
evaluated the time until dye diffusion was established between
CSCs and between non-CSCs as an indicator of the gap-junction-(H) Kaplan-Meier plots of intracranial transplantation of 1,000 (top) or 10,000 (botto
increased tumor latency. Tubulin and actin were used as protein loading controls
differentiation.
Data in graphs represent mean values ± SD; *p < 0.05, **p < 0.01 as assessed
significance for in vivo studies. See also Figure S2.
Cforming capacity of these cells. We observed that the establish-
ment of new gap junctions was significantly faster in CSCs
compared with non-CSCs (Figure 5B). Depletion of Cx46 from
CSCs by shRNA resulted in decreased dye diffusion (Figure 5C),
suggesting that new gap junctions formed more slowly and
demonstrating the role of Cx46 in this process.
We voltage-clamped CSCs and non-CSC and observed a
decreased outward current in CSCs (Figure 5D) and significantly
depolarized resting membrane potential (Figure 5E), which may
be due to a decrease in cell membrane ionic permeability for
potassium ions. Whole-cell voltage clamp analysis revealed
reduced potassium current density in CSCs compared with
non-CSCs (data not shown). Based on differences in connexin
expression between CSCs and non-CSCs as well as the rate ofm) CSCs with reduced Cx46 expression show decreased tumor formation and
, and a reduction in Sox2 expression was used as a positive control to confirm
by one-way ANOVA and log-rank analysis were used to calculate statistical
ell Reports 11, 1031–1042, May 19, 2015 ª2015 The Authors 1037
Figure 6. Bioinformatics Analysis of Cell
Junction Proteins Reveals a Negative Corre-
lation between Cx46 and GBM Patient Sur-
vival
(A and B) Cx46 negatively correlated with overall
glioma andGBMpatient survival as assessed by the
NCI REMBRANDT database (A) and with GBM pa-
tient survival in TCGA classical molecular subtype
(B).
(C and D) Cx43 did not correlate with overall glioma
or GBM patient survival as assessed by the NCI
REMBRANDT database (C) or with GBM patient
survival in TCGA classical molecular subtype (D).
Statistical assessments were performed using log-
rank survival analysis and p values are indicated
directly on survival plots.
See also Figure S3.cell-cell communication and resting membrane potential, we set
out to determine whether the expressions of Cx46 and Cx43
were linked as reported in the lens (Banerjee et al., 2011). To
evaluate whether Cx43 suppressed Cx46 expression in GBM
cells, we generated non-overlapping shRNA constructs against
the Cx43 mRNA (Figure S2B) and found that a reduction in
Cx43 in non-CSCs resulted in an increase in Cx46 (Figure 5F).
Non-CSCs depleted of Cx43 possessed an increasedmembrane
potential, with the values for some cells falling within the range of
values observed for CSCs (Figure 5G), and this result was consis-
tent with the increased level of Cx46 in these cells. Taken
together, these data suggest that the differential expression of
connexin subunits between CSCs and non-CSCs is in part linked
to the differentiation process and that these changes in connexin
subunits affect de novo gap junction formation and resting
membrane potential.
Cx46, but Not Cx43, Expression Predicts GBM Patient
Survival
Based on our observations of the roles of gap junctions and indi-
vidual connexin subunits in GBM cells, we sought to determine
whether expression differences correlated with GBM patient
prognosis. We first analyzed bioinformatics data to determine
whether changes in the molecules expressed at cell-cell inter-
faces, including connexins, predicted GBM patient prognosis
by interrogating the tight junction interaction gene set in Onco-
mine, which contains 26 genes expressed at cell junctions
including some connexin subunits (Figure S3A). As a whole,
elevated levels in this gene set significantly correlated with poor
glioma patient prognosis (Figure S3B) and included proteins
that previously have been reported in GBM progression, such
as epidermal growth factor receptor (EGFR) (Mazzoleni et al.,
2010) and junctional adhesion molecule-A (JAM-A), which we
recently reported to be elevated in CSCs (Lathia et al., 2014).1038 Cell Reports 11, 1031–1042, May 19, 2015 ª2015 The AuthorsWe interrogated the correlation between
expression levels of individual genes and
GBM patient survival across multiple
other datasets in both Oncomine and
the National Cancer Institute (NCI) Repos-
itory for Molecular Brain Neoplasia Data(REMBRANDT) and found that Cx46 elevation consistently
correlated with poor prognosis of glioma and GBM patients (Fig-
ure 6A; Figure S3C). Cx46 also negatively correlated with patient
survival in the classical molecular subtype in The Cancer
Genome Atlas (TCGA) dataset, but did not correlate with survival
in the mesenchymal or proneural subtypes (Figure 6B, data not
shown). Cx43 showed no consistent correlation with patient sur-
vival (Figures 6C and 6D; Figure S3C), nor did other connexin
subunits in the dataset (Cx31, Cx43, Cx45, and Cx50; data not
shown). Taken together, our bioinformatics analysis revealed
that proteins expressed at intercellular junctions inform GBM
patient survival and demonstrated that Cx46 levels correlate
with poor GBM patient prognosis, which support our findings
that Cx46 is essential for CSC maintenance.
DISCUSSION
Gap junctions have been shown to play a tumor-suppressive
role (Kandouz and Batist, 2010); however, our data indicate
that the connexin composition of gap junctions dictates their
function, which can be tumorigenic. Gap-junction-mediated
communication plays critical roles in coordinating many cellular
processes, such as electrophysiological activity, proliferation,
cell survival, and differentiation to maintain tissue homeostatic
integrity (Wei et al., 2004; White and Paul, 1999). Therefore,
reduced expression of connexins has been considered a mech-
anism that enables tumor cells to escape from the instructions of
the tissue and obtain malignant phenotypes, such as continued
proliferation, uncontrolled migration, and invasion. Reduced
connexin levels have been reported in GBM, and restoring
expression inhibited tumor growth (Hao et al., 2012; Huang
et al., 2002; Soroceanu et al., 2001; Yu et al., 2012). However,
our study uncovers a pro-tumorigenic role for Cx46 that is essen-
tial for CSC maintenance. Similar roles for gap junctions have
been experimentally demonstrated in somatic stem cells during
regeneration (Foss et al., 2009; Ja¨derstad et al., 2010), in the
germline (Tazuke et al., 2002), and in embryonic stem cells (To-
dorova et al., 2008; Wong and Pe´bay, 2010). Based on the
pro- and anti-tumor effects of connexins, a comprehensive
investigation of gap junctions that takes into account connexin
diversity will be required to understand the role of gap junctions
during tumor growth.
Our observation that Cx46 and Cx43 exist on different ends
of the differentiation spectrum of GBM cells supports diverse
roles for connexins and suggests that connexin specificity
may be essential for transitions between self-renewal and dif-
ferentiation. Our data also confirm previous findings in the
lens by showing that Cx43 reduction in non-CSCs increases
Cx46 expression. However, unlike the reciprocal relationship
between Cx46 and Cx43 in the lens (Banerjee et al., 2011),
knockdown of Cx46 in CSCs did not increase Cx43 expression,
or self-renewal, or resting membrane potential, nor did overex-
pression of Cx46 in non-CSCs decrease Cx43 expression (data
not shown), suggesting that there are additional regulatory ele-
ments between Cx46 and Cx43. These observations raise a
fundamental question: why do different cells require different
connexins? Several possibilities exist including the physical
properties of cell-cell communication (speed of communication
and ion selectivity) that may result in differences in membrane
potential depolarization serving as an electrical signal to acti-
vate voltage-dependent plasma membrane proteins. This hy-
pothesis is supported by our observation that CSCs exhibit
elevated dye diffusion, a surrogate for increased gap junction
coupling, and have a reduced resting membrane potential.
The differences in resting membrane potential also may reflect
an indirect regulation of ion diffusion, which would be a useful
area for future inquiry.
Interestingly, we observed a correlation between high Cx46
expression and poor patient prognosis in the classical subtype,
but not in the proneural or mesenchymal subtypes, of GBM. The
difference in the proneural molecular subtype where Cx43
was more negatively correlated with patient prognosis may be
related to observations of inhibition of gap-junction-mediated
intercellular communication by platelet-derived growth factor
(PDGF) signaling (Yao et al., 2000), a hallmark mutation in the
subtype; thus, a decreased reliance on gap junction communi-
cation mediated by PDGF receptor signaling in the proneural
subtype may reduce the selective pressure to express specific
connexin isoforms. Additional connexin-specific evaluations
will be required to fully elucidate the contribution of connexin
subunits to self-renewal and modulation of physical properties.
In addition, future studies also need to consider the growing ev-
idence that connexin function may be controlled by cytoplasmic
tail interactions (Dbouk et al., 2009), the interaction between
individual connexin subunits and scaffolding proteins or cadher-
ins, such as the recently demonstrated interaction between
Cx43 and E-cadherin (Yu et al., 2012), which may provide addi-
tional opportunities to unravel the complexity of connexin action
during tumorigenic processes as well as reveal points of fragility
for therapeutic targeting.
Our data also indicate that cell-cell communication is critical
for tumor growth and highlight the complexity of anti-tumor ap-Cproaches through connexin targeting that have mainly focused
on increasing connexin expression and gap junction function.
Reduced connexin expression in tumors supports a therapeutic
approach in which increasing gap junctions would elicit a ther-
apeutic benefit and would be expected to maximize the
bystander effect to increase therapeutic efficacy against tumor
cells (Cottin et al., 2011). However, recent work has demon-
strated that Cx43 is linked to TMZ resistance, which can be
reversed by reducing Cx43 expression (Gielen et al., 2013; Mu-
noz et al., 2014), thereby supporting a therapeutic approach
based on reducing connexin levels. Our data indicate that tar-
geting gap junction function using inhibitors, such as 1-octanol
and CBX, is associated with attenuated CSC maintenance and
tumor progression. While these results must be interpreted in
the context of these inhibitors targeting multiple connexin sub-
units, our genetic approach specifically targeting Cx46, which
is enriched in CSCs, revealed an essential role of this connexin
subunit in CSC maintenance and GBM growth. The gap junc-
tion inhibitors tested in this study are approved for clinical
use, and 1-octanol is currently under investigation for essential
tremor (Nahab et al., 2011; Shill et al., 2004). The activity of
these inhibitors against GBM encourages the clinical applica-
tion of these agents to treat GBM, a disease that responds
poorly to current therapeutics.
To pursue this direction, determining the effective and toler-
able concentrations of gap junction inhibitors is an important
next step, because gap junctions function ubiquitously in
many organs and tissues to regulate physiological functions.
Hence, it would be desirable to develop inhibitors with spec-
ificity for the connexin isotype essential for CSCs, such as
Cx46, although the anti-tumor dosages of general gap junc-
tion inhibitors were tolerated in our current in vivo animal
models. In addition to their own anti-GBM effects, these gap
junction inhibitors enhanced the anti-tumor effect of TMZ,
the standard chemotherapeutic agent used to treat GBM,
which also was observed in recent studies on Cx43 (Gielen
et al., 2013; Munoz et al., 2014). Furthermore, we demonstrate
that gap junction inhibitors can sensitize TMZ-resistant
GBM cells. These findings suggest that gap junction inhibitors
can be used to override the development of TMZ resistance
and potentially that of other chemotherapy drugs as well.
Similarly, gap junction inhibition is reported to enhance the
cytotoxicity induced by TRAIL stimulation in glioma (Yulyana
et al., 2013). The presence of a gap junction network system
among tumor cells in GBM, as demonstrated by this study,
contributes to CSC maintenance and tumor growth in a
connexin-isotype-dependent manner and provides a unique
therapeutic opportunity for the development of more effective
anti-GBM therapies.EXPERIMENTAL PROCEDURES
GBM Cell Collection, Culture, and Usage
GBM cells were dissociated from specimens collected from patients, under
written consent according to a protocol approved by the Cleveland Clinic
and University of Florida Institutional Review Boards, and maintained as
subcutaneous xenografts. CSCs and non-CSCs were generated from these
xenografts as described in the Supplemental Experimental Procedures.ell Reports 11, 1031–1042, May 19, 2015 ª2015 The Authors 1039
Proliferation, Sphere Formation, and Tumor Initiation Assays
Cell proliferation, self-renewal, and tumor initiation assays were performed as
previously described (Bao et al., 2006; Eyler et al., 2011; Guryanova et al.,
2011; Lathia et al., 2010; Li et al., 2009). Relevant experimental details are
described in the Supplemental Experimental Procedures.
Electron Microscopy
CSC spheres were collected by centrifugation, and subcutaneous xenograft
tumors were obtained by cutting a portion of the tumors into small pieces
less than 1 mm3. The samples were fixed with 10% formaldehyde, 2% para-
formaldehyde, 2.5% glutaraldehyde, and 2.5% dimethyl sulfoxide in Millonig’s
phosphate buffer for 2 hr at room temperature. After rinsing, the specimens
were post-fixed with 3% potassium ferrocyanide and 2% aqueous osmium
tetroxide twice for 1 hr each. Samples were stained with 0.25% uranyl acetate,
dehydrated, and embedded into propylene oxide resin. Thin sections were
made and observed with transmitted electron microscopes, either an FEI
Tecnai G2 Spirit BioTWIN or a JEOL 1200EX electron microscope.
Immunofluorescence Analysis
Immunostaining analysis on xenografted GBM specimens (generated by intra-
cranial injection of GBM specimens T4121 and T387) was performed as previ-
ously described (Lathia et al., 2010). Relevant experimental details are
described in the Supplemental Experimental Procedures.
Gap Junction Dye Diffusion Assay
To quantify gap-junction-mediated intercellular diffusion, we used three
separate approaches: (1) analyzing diffusion of calcein from loaded cells by
flow cytometry, (2) analyzing calcein diffusion by time-lapse imaging, and (3)
performing microinjection-based analysis. The flow cytometric determination
was performed similarly as described previously (Fonseca et al., 2006).
A single-cell suspension was prepared by trypsinizing a CSC sphere culture
the day before the assay. The suspension was separated into two fractions.
The donor cells were loaded with calcein AM, and the acceptor cells were
labeled with DiD according to the manufacturer’s instructions. After the free
dye was washed away, both cultures were mixed for various times, stained
with DAPI, and fixed with paraformaldehyde. Fluorescence-activated cell
sorting (FACS) data were analyzed after gating to eliminate aggregated cells
(by forward and side scattering) and dead cells (by DAPI positivity). The per-
centage of recipient cells that became positive for calcein signal was deter-
mined. To analyze the kinetics of dye coupling, we also monitored calcein
diffusion using time-lapsemicroscopy. Calcein AM-loaded, DiD-labeled donor
cells in suspension were plated onto monolayer cultures of unlabeled recipient
cells. To determine gap junction activity, recorded images were analyzed for
the density of calcein dye uptake by unlabeled cells and calcein retained by
DiD-labeled donor cells using ImageJ.
To determine gap-junction-dependent dye diffusion, cells were grown on
a coverslip coated with Geltrex and cultured in neurobasal media with B27,
EGF, and bFGF. A single cell was co-injected with lucifer yellow or 2-deoxy-
2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (2NBDG), a fluores-
cent glucose analog, together with Cy5-labeled IgG. Immediately after micro-
injection, time-lapse video microscopy was used to capture phase contrast,
green fluorescent (for lucifer yellow or 2NBDG), and far-red fluorescent (for
Cy5 IgG) images. The Cy5 IgG image defines the initially injected donor cells,
and the green signal outside of this donor cell is the dye diffused to neighboring
cells. The fluorescent signals of the dye retained in the donor cells and the dye
exported were quantified after thresholding green and far-red fluorescent
images using the Wand tool of ImageJ.
qPCR and Immunoblot Analysis
The qPCR and immunoblot analysis was performed as previously described
(Bao et al., 2006; Eyler et al., 2011; Guryanova et al., 2011; Lathia et al.,
2010; Li et al., 2009). Relevant experimental details are described in the
Supplemental Experimental Procedures.
Patch Clamping to RecordMembrane Potentials and Inward Current
CSCs and non-CSCs were plated at low density in 35-mm dishes and incu-
bated at 37C in 10% CO2 for at least 24 hr before recording using the1040 Cell Reports 11, 1031–1042, May 19, 2015 ª2015 The Authorswhole-cell configuration of the patch-clamp technique at room temperature
(22C–24C). Patch pipettes (3.5–4.5 MU) were pulled (P-1000, Sutter Instru-
ments) from micropipette glass (Fisher Scientific) and fire-polished (MF-830,
Narashige). Recording pipettes contained the following: KCl (130 mM),
EGTA (10 mM), HEPES (10 mM), CaCl2 (1 mM), and MgCl2 (1 mM [pH 7.3]).
For CSCs and non-CSCs, the bath solution contained the following: NaCl
(136 mM), KCl (4 mM), MgCl2 (2 mM), CaCl2 (1 mM), HEPES (10 mM), and
glucose (10 mM [pH 7.4]).
Current-clamp experiments were performed to record the cell’s resting
membrane potential. All voltage- and current-clamp experiments were per-
formed using an Axopatch 200B amplifier (Molecular Devices) interfaced to
a Dell Precision T1600 computer with a Digidata 1440 analog/digital interface
and the pCLAMP 10 software package (Molecular Devices). Data were
filtered at 5 kHz before storage and offline analysis (Clampfit10). Voltage
protocols were delivered at 10-s intervals. Approximately 80% of series
resistance was compensated with the voltage-clamp circuitry. Inward and
outward currents were recorded in response to 10-ms voltage steps to
test potentials between 120 and +80 mV from a holding potential (HP)
of 80 mV.
Bioinformatics Analysis
The Oncomine Platform (Life Technologies) was used for analysis of patient
data. Genes used to form the tight junction index were taken from the Human
Protein ReferenceDatabase (HPRD) interaction set with tight junction protein 1
(TJP1), accessed through Oncomine. Expression levels of these genes were
combined to create a tight junction index for each patient with survival data
from the available datasets. Survival comparisons are between patients
with higher- or lower-than-average gene expression or tight junction index
score, visualized via Kaplan-Meier analysis and assessed for significance
via log-rank test. Oncomine data were accessed at https://www.oncomine.
org. NCI REMBRANDT data were accessed at https://caintegrator.nci.nih.
gov/rembrandt/. TCGA data were accessed at https://tcga-data.nci.nih.gov/
tcga/tcgaHome2.jsp.
ChIP-Seq Analysis
We obtained published datasets of histone H3K27ac ChIP-seq data (Suva`
et al., 2014) and normal brain regions (ENCODE consortium), and we viewed
the aligned data using the Integrative Genomics Viewer (IGV) browser tool
(Broad Institute, https://www.broadinstitute.org). Track scales were matched
among all paired samples.
Statistical Analysis
Values reported in the results are mean values ± SD, and statistical analysis
was performed using Sigma Stat (version 3.5). Unless otherwise stated, one-
way ANOVA was used to calculate statistical significance; p values are
detailed in the text and figure legends. In vivo survival analysis was calculated
by log-rank analysis.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.04.021.AUTHOR CONTRIBUTIONS
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